Table 1.
Comparison of recipient, intraoperative, donor, and post-transplant factors of patients with immunosuppressive management by the paper charting system versus the automated clinical management system
| Factors |
Paper charting system N=301 | Automated system N=127 | |
| Recipient | Mean±SD (%) | Mean±SD (%) | p†† |
| Age, years | 53.5±8.5 | 52.5±8.9 | 0.3 |
| Male | 73% | 72% | 0.8 |
| White | 87% | 89.% | 0.7 |
| African-American | 2% | 2% | 0.7 |
| Asian | 9% | 5% | 0.2 |
| Other races | 2% | 4% | 0.9 |
| Patient needs interpreter | 7% | 4% | 0.2 |
| Re-transplantation | 3% | 6% | 0.3 |
| Hepatitis B virus infection | 4% | 6% | 0.7 |
| Hepatitis C virus infection | 56% | 50% | 0.2 |
| Alcoholic liver disease | 8% | 12% | 0.3 |
| Cryptogenic cirrhosis | 5% | 6% | 0.8 |
| Acute hepatic necrosis | 2% | 0% | 0.2 |
| Cholestatic liver disease | 11% | 10% | 0.6 |
| Other liver disease diagnosis | 10% | 12% | 0.5 |
| HCC with MELD exception | 19% | 2% | <0.001 |
| Cerebral/cardiovascular disease | 4% | 1% | 0.07 |
| Renal disease | 7% | 6% | 0.8 |
| Diabetes* | 21% | 21% | 0.9 |
| Hypertension | 19% | 21% | 0.7 |
| BMI | 29±5.3 | 29±4.9 | 0.7 |
| Status 1 | 0% | 2% | 0.6 |
| TIPS† | 7% | 2% | 0.1 |
| On dialysis time of transplant | 2% | 2% | 0.7 |
| Pre-transplant serum creatinine, mg/dl | 1.3±1.1 | 1.4±1.5 | 0.5 |
| Pre-transplant total bilirubin, mg/dl | 5±7.2 | 5.9±9.9 | 0.4 |
| Pre-transplant cholesterol, mg/dl | 141.6±54.1 | 144.4±61.7 | 0.7 |
| Intraoperative and donor | |||
| Identical blood type | 94% | 94% | 1 |
| Compatible blood type | 5% | 5% | 1 |
| Incompatible blood type | 1% | 2% | 0.6 |
| Split liver | 1% | 0% | 0.6 |
| Simultaneous kidney transplant | 4% | 3% | 0.8 |
| Cold ischemia time, min‡ | 428.8±164.9 | 493±149 | 0.001 |
| Warm ischemia time, min§ | 35.8±7.9 | 42±10 | <0.001 |
| Units PRBC transfused (250 ml) | 3.3±2.9 | 3.8±3.2 | 0.2 |
| Donation after cardiac death donor | 13% | 7% | 0.09 |
| Donor age, years | 39.8±16.5 | 36.4±14.2 | 0.04 |
| Donor male | 64% | 69% | 0.4 |
| Donor race white | 82% | 74% | 0.06 |
| Donor race African-American | 3% | 2% | 0.5 |
| Donor race Asian | 6% | 2% | 0.09 |
| Donor race other | 8% | 22% | <0.001 |
| Donor BMI | 26.6±6.1 | 27.3±5.1 | 0.2 |
| Greater 20% fat in liver biopsy | 3% | 1% | 0.3 |
| Post-transplant | |||
| Induction with ATG¶ | 24% | 80% | <0.001 |
| MMF** | 28% | 554% | <0.001 |
| Prednisone | 33% | 18% | 0.001 |
Diabetes mellitus requiring insulin.
Transjugular intrahepatic portosystemic shunt.
Time from placing donor liver on ice during the procurement until removal from ice at time of transplant.
Time from removal of liver from ice at time of transplant until recirculation of blood to liver.
Anti-thymocyte globulin.
Mycophenolate mofetil.
Student's t-test was used for testing continuous variables, and the Fisher's Exact test was used for categorical variables.
ATG, anti-thymocyte globulin; BMI, body mass index; HCC, hepatocellular carcinoma; MELD, model for end-stage liver disease; MMF, mycophenolate mofetil; PRBC packed red blood cells; TIPS, transjugular intrahepatic portosystemic shunt.